Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALLO

ALLO - Allogene Therapeutics Inc Stock Price, Fair Value and News

4.36USD-0.08 (-1.80%)Market Closed
Watchlist

Market Summary

USD4.36-0.08
Market Closed
-1.80%

ALLO Stock Price

View Fullscreen

ALLO RSI Chart

ALLO Valuation

Market Cap

733.7M

Price/Earnings (Trailing)

-2.2

Price/Sales (Trailing)

3.9K

EV/EBITDA

-2.9

Price/Free Cashflow

-2.94

ALLO Price/Sales (Trailing)

ALLO Profitability

EBT Margin

-138174.73%

Return on Equity

-57.08%

Return on Assets

-46.73%

Free Cashflow Yield

-33.96%

ALLO Fundamentals

ALLO Revenue

Revenue (TTM)

186.0K

Rev. Growth (Yr)

-12.24%

Rev. Growth (Qtr)

-2.27%

ALLO Earnings

Earnings (TTM)

-332.9M

Earnings Growth (Yr)

26.26%

Earnings Growth (Qtr)

21.38%

Breaking Down ALLO Revenue

Last 7 days

9.4%

Last 30 days

48.8%

Last 90 days

62.4%

Trailing 12 Months

-30.3%

How does ALLO drawdown profile look like?

ALLO Financial Health

Current Ratio

12.58

ALLO Investor Care

Shares Dilution (1Y)

16.69%

Diluted EPS (TTM)

-2.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023234.0K192.0K186.0K0
202228.9M19.4M9.8M243.0K
202100038.5M

Tracking the Latest Insider Buys and Sells of Allogene Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 25, 2024
chang david d
acquired
-
-
317,800
president and ceo
Jan 25, 2024
roberts zachary
acquired
-
-
140,000
evp of r&d
Jan 25, 2024
belldegrun arie
acquired
-
-
211,973
-
Jan 25, 2024
douglas earl martin
acquired
-
-
41,800
svp, general counsel
Jan 25, 2024
moore timothy l.
acquired
-
-
96,600
chief technical officer
Jan 25, 2024
parker geoffrey m.
acquired
-
-
29,400
chief financial officer
Jan 22, 2024
roberts zachary
sold (taxes)
-78,375
3.1744
-24,690
evp of r&d
Dec 18, 2023
messemer deborah m.
sold
-50,316
2.6994
-18,640
-
Oct 16, 2023
parker geoffrey m.
acquired
-
-
790,000
chief financial officer
Aug 14, 2023
douglas earl martin
acquired
-
-
435,834
general counsel

1–10 of 50

Which funds bought or sold ALLO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 21, 2024
Raleigh Capital Management Inc.
new
-
8,844
8,844
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-1.49
-19,000
7,613,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-83.82
-336,000
66,000
0.01%
Feb 15, 2024
Virtus ETF Advisers LLC
added
72.24
46,786
109,663
0.07%
Feb 15, 2024
JANE STREET GROUP, LLC
added
1,239
1,061,250
1,145,740
-%
Feb 15, 2024
Legal & General Group Plc
added
1.04
5,972
263,721
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
1,021
1,021
-%
Feb 15, 2024
BARCLAYS PLC
reduced
-76.5
-1,901,000
594,000
-%
Feb 15, 2024
HORIZON KINETICS ASSET MANAGEMENT LLC
reduced
-4.03
-1,787
61,613
-%
Feb 15, 2024
GTS SECURITIES LLC
sold off
-100
-34,851
-
-%

1–10 of 46

Are Funds Buying or Selling ALLO?

Are funds buying ALLO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALLO
No. of Funds

Unveiling Allogene Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
chang david d
5.8%
9,964,347
SC 13G/A
Feb 14, 2024
belldegrun arie
5.8%
9,895,903
SC 13G/A
Feb 13, 2024
vanguard group inc
5.37%
9,030,825
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 29, 2024
blackrock inc.
5.9%
10,001,804
SC 13G/A
Jan 23, 2024
state street corp
1.44%
2,427,284
SC 13G/A
Oct 25, 2023
pfizer inc
13.14%
22,032,040
SC 13D/A
Jul 10, 2023
fmr llc
-
0
SC 13G
Feb 13, 2023
chang david d
5.7%
8,427,632
SC 13G
Feb 13, 2023
belldegrun arie
6.1%
8,858,861
SC 13G/A

Recent SEC filings of Allogene Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 16, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading

Peers (Alternatives to Allogene Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Allogene Therapeutics Inc News

Latest updates
InvestorsObserver08 Feb 202408:00 am
Yahoo Finance12 Jan 202408:00 am
Seeking Alpha05 Jan 202408:00 am

Allogene Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue-2.3%43.0044.0052.0047.0049.0086.0069.0051.0049.0044.0038,345
Operating Expenses-21.8%63,01880,56299,12296,42182,53876,68080,05373,94477,71971,07371,546
  S&GA Expenses-8.0%17,04118,52418,88421,00218,89719,50919,89719,96118,99918,78316,363
  R&D Expenses-25.9%45,97762,03880,23875,41963,64157,17160,15653,98358,72052,29055,183
EBITDA Margin-3.3%-1.31-1.27-1.04-998.81*-24.64*-12.55*-8.46*-6.41*---
EBT Margin-3.2%-1.38-1.34-1.10-1.06-26.21*-13.27*-8.88*-6.68*---
Net Income21.4%-61,315-77,989-98,704-94,847-83,148-74,787-79,850-74,868-78,186-70,936-33,015
Net Income Margin3.1%-1.79-1.85-1.50-1.37-31.89*-15.89*-10.50*-6.68*---
Free Cashflow10.6%-55,542-62,145-67,674-63,788-47,878-43,905-70,139-46,172-52,225-52,072-55,789
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-7.6%7127717478178889489651,0391,0791,1271,1791,2281,2231,259689718696734749774435
  Current Assets-5.7%473502481529569513470471503602716845854910504545510512477468247
    Cash Equivalents-55.3%69.0015511062.0085.0010695.0018419923324619316828514017916511797.0094.0084.00
  Net PPE-3.3%10310611011311411712012312612512311910385.0066.0056.0046.0036.0020.009.005.00
Liabilities-12.7%12914815515114814610912210910310914810495.0082.0089.0076.0078.0068.0071.00193
  Current Liabilities-31.2%38.0055.0060.0055.0049.0045.0037.0048.0053.0046.0055.0094.0050.0041.0027.0033.0033.0038.0027.0029.00159
Shareholder's Equity-6.4%5836235926667408028559169701,0241,0701,0801,1191,16360762962065668170313.00
  Retained Earnings-5.3%-1,473-1,400-1,334-1,235-1,141-1,057-983-903-828-750-679-646-577-511-450-396-335-284-243-211-181
  Additional Paid-In Capital1.0%2,0592,0391,9331,9121,8941,8711,8481,8221,7991,7741,7491,7261,6951,6731,0551,02495393892391413.00
Shares Outstanding0.6%168167146144144142141143135134132120---------
Float------1,009---2,254---3,509---1,601---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations10.2%-55,530-61,857-66,639-62,096-47,655-42,531-68,237-45,436-48,878-41,170-49,328-9,975-37,588-26,721-40,809-50,267-31,935-24,892-30,256-21,481-17,130
  Share Based Compensation-7.5%15,35416,59418,77017,24621,14822,89122,31522,03620,85621,13416,79216,45317,82316,77014,21513,87412,83511,4877,8675,8714,639
Cashflow From Investing-299.7%-34,26717,160112,93549,59724,90554,034-22,37729,25013,01324,59496,79822,210-83,355-428,971-15,0077,92978,77544,49232,888-313,388-316,776
Cashflow From Financing-95.2%4,28589,5241,73146.001,06624.001,8143222,3833,2146,04412,9783,852600,17516,58656,4741,566236684344,522274,057

ALLO Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues    
Collaboration revenue - related party$ 43$ 49$ 139$ 196
Operating expenses:    
Research and development45,97763,641188,253180,968
General and administrative17,04118,89754,44958,303
Total operating expenses63,01882,538242,702239,271
Loss from operations(62,975)(82,489)(242,563)(239,075)
Other income (expense), net:    
Interest and other income, net6,2051,00212,0421,809
Other expenses(4,545)(1,661)(7,487)(519)
Total other income (expense), net1,660(659)4,5551,290
Net loss(61,315)(83,148)(238,008)(237,785)
Other comprehensive loss:    
Net unrealized gain (loss) on available-for-sale investments1,440(1,486)7,515(10,391)
Net comprehensive loss$ (59,875)$ (84,634)$ (230,493)$ (248,176)
Net loss per share, basic (in dollars per share)$ (0.37)$ (0.58)$ (1.55)$ (1.67)
Net loss per share, diluted (in dollars per share)$ (0.37)$ (0.58)$ (1.55)$ (1.67)
Weighted-average number of shares used in computing net loss per share, basic (in shares)167,649,010143,661,721153,087,449142,809,469
Weighted-average number of shares used in computing net loss per share, diluted (in shares)167,649,010143,661,721153,087,449142,809,469

ALLO Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 69,246$ 61,904
Short-term investments396,259455,416
Prepaid expenses and other current assets7,94911,504
Total current assets473,454528,824
Long-term investments32,17059,151
Operating lease right-of-use asset78,64383,592
Property and equipment, net102,826112,839
Restricted cash10,29210,292
Other long-term assets9,5769,564
Equity method investment5,36512,817
Total assets712,326817,079
Current liabilities:  
Accounts payable6,20513,890
Accrued and other current liabilities31,19539,743
Deferred revenue236885
Total current liabilities37,63654,518
Lease liability, non-current90,10295,122
Other long-term liabilities1,4861,569
Total liabilities129,224151,209
Commitments and Contingencies (Notes 6 and 7)
Stockholders’ equity:  
Preferred stock, $0.001 par value: 10,000,000 shares authorized as of September 30, 2023 and December 31, 2022; no shares were issued and outstanding as of September 30, 2023 and December 31, 202200
Common stock, $0.001 par value: 400,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 168,175,221 and 144,438,304 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively168144
Additional paid-in capital2,059,3331,911,632
Accumulated deficit(1,473,988)(1,235,980)
Accumulated other comprehensive loss(2,411)(9,926)
Total stockholders’ equity583,102665,870
Total liabilities and stockholders’ equity$ 712,326$ 817,079
ALLO
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.allogene.com
 EMPLOYEES359

Allogene Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Allogene Therapeutics Inc? What does ALLO stand for in stocks?

ALLO is the stock ticker symbol of Allogene Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allogene Therapeutics Inc (ALLO)?

As of Thu Feb 22 2024, market cap of Allogene Therapeutics Inc is 733.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALLO stock?

You can check ALLO's fair value in chart for subscribers.

What is the fair value of ALLO stock?

You can check ALLO's fair value in chart for subscribers. The fair value of Allogene Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allogene Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALLO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allogene Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALLO is over valued or under valued. Whether Allogene Therapeutics Inc is cheap or expensive depends on the assumptions which impact Allogene Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLO.

What is Allogene Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ALLO's PE ratio (Price to Earnings) is -2.2 and Price to Sales (PS) ratio is 3.94 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALLO PE ratio will change depending on the future growth rate expectations of investors.